@article{712bc22050304f62a36ecec91682f7f2,
title = "Single-fraction SBRT for Early Stage NSCLC-A Viable Option in “These Uncertain Times”?",
author = "Salama, {Joseph K.} and Giuliani, {Meredith E.} and Robinson, {Clifford G.} and Daly, {Megan E.}",
note = "Funding Information: Disclosures: J.K.S. receives funding from AbbVie, Merck, Array, and BMS. M.G. receives funding from Elekta, AstraZeneca, and BMS. C.R. receives research funding from Elekta, Varian, and Merck; is a consultant for AstraZeneca, EMD Serono, and Radialogica; and holds equity in Radialogica. M.E.C. receives research funding from EMD Serono and Genentech and is a consultant for Boston Scientific and Triptych Health Partners. ",
year = "2021",
month = jan,
day = "1",
doi = "10.1016/j.ijrobp.2020.08.031",
language = "English (US)",
volume = "109",
pages = "1--4",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",
}